GlaxoSmithKline to begin human trials for HIV cure

GSK is aiming to find a cure for HIV while also developing longer-acting drug treatments and preventive therapies.


Tech Desk November 30, 2021
Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS/Matthew Childs/File Photo

GlaxoSmithKline, the British pharmaceutical company is planning to conduct human trials to find a cure for HIV, Money Control reported.

A Kaiser Family Foundation study recently found that in 2019, 38 million people globally were living with HIV. Thus, the trials by the pharmaceutical company would be a ground-breaking effort to find a cure to a common disease. The company would try to wake up a latent HIV virus within the participant's immune system through therapies. Efforts would then be made to neutralise the virus once it's activated in the body.

Dr Kimberly Smith, head of research and development at GSK's HIV health division ViiV healthcare, said, "The idea is that you have to wake up the latent virus and try to get rid of it."

The British Daily reported that a similar trial on non-human primates was successful in making the cells identify themselves. 

While treatments have been discovered for HIV, there is yet a cure to be found, since treatments allow the patients to live a longer life with the virus. GSK already offers injection therapies as a treatment for HIV, where patients can just inject themselves once a month instead of taking pills every day. The company wants to make their injection therapies long-lasting, which would require their patients to inject themselves once every six months. 

GSK is also reportedly working to make longer-acting preventive drugs for HIV which can be used in long gaps. The drugs would also be available for use for people at high risk of HIV due to close contact.

 

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ

E-Publications

Most Read